Stoke Therapeutics (STOK) Operating Income Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Operating Income Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -18.82% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 81.27% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -25.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.30% |
| Mar 31, 2026 | -29.34% |
| Dec 31, 2025 | -31.25% |
| Sep 30, 2025 | -16.65% |
| Jun 30, 2025 | -2.65% |
| Mar 31, 2025 | 86.50% |
| Dec 31, 2024 | 17.74% |
| Sep 30, 2024 | -9.77% |
| Jun 30, 2024 | -10.03% |
| Mar 31, 2024 | -19.02% |
| Dec 31, 2023 | -26.59% |
| Sep 30, 2023 | -25.70% |
| Jun 30, 2023 | -36.73% |
| Mar 31, 2023 | -28.14% |
| Dec 31, 2022 | -34.90% |
| Sep 30, 2022 | -40.24% |
| Jun 30, 2022 | -44.04% |
| Mar 31, 2022 | -57.70% |
| Dec 31, 2021 | -75.44% |
| Sep 30, 2021 | -89.81% |